NanoCur: a curcumin derivative being studied in CMT 1A

Curcumin is known to have antioxidant and neuroprotective effects, but it degrades too quickly in the body to make a good drug candidate. NanoCur is a compound developed from curcumin, with improved pharmacokinetic characteristics. It was developed by researchers at the University of Limoges, with the support of the AFM-Téléthon, to target nerve damage in Charcot-Marie-Tooth 1A disease.

  • NanoCur was administered daily to rodent models of CMT 1A for 8 to 12 weeks.
  • It improved the motor skills of treated animals through better myelination of nerve fibres,
  • No toxicity was observed.

 

Improvement of Charcot-Marie-Tooth Phenotype with a Nanocomplex Treatment in Two Transgenic Models of CMT1A. El Massry M , Msheik Z, Tarek El Masri T, et al. Biomater Res . 2024 Mar